Leukemia, Acute Myelogenous (AML): Clinical Trials

2 trials for Leukemia, Acute Myelogenous (AML), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 unknown. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 1, Unknown 1
Phase 21Completed 1

Follow Leukemia, Acute Myelogenous (AML): new trials by email Literature Review of Leukemia, Acute Myelogenous (AML) trials Research Report on Leukemia, Acute Myelogenous (AML)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Chimeric antigen receptor T cells, peptide specific dendritic cell - Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML)
Phase 1UnknownZhujiang Hospital302018-05-052024-03-15
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4 - Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL)
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)102008-02-222017-04-12

Narrower conditions

Leukemia (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Myelodysplastic Syndromes (2)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Broader conditions

Bone Marrow Diseases (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Leukemia, Myeloid (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Leukemia, Lymphoid (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoproliferative Disorders (1)  ·  Myeloproliferative Disorders (1)

Interventions

Acetaminophen (1)  ·  Diphenhydramine (1)  ·  Endotoxins (1)  ·  Immunotherapy, Adoptive (1)  ·  Interleukin-4 (1)  ·  keyhole-limpet hemocyanin (1)

Sponsors

National Cancer Institute (NCI) (1)  ·  Zhujiang Hospital (1)

Countries

China (1)  ·  United States (1)

Top investigators

Terry J Fry, M.D. (1)  ·  Yuhua Li, M.D, Ph.D (1)

Results publications

PMID 38712616